Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ILT2.4-1BB.CD3ζ CIR-NK cells
- Development stage
- Preclinical
- Lead developer
- NKILT Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
ILT2.4-1BB.CD3ζ CIR-NK cells are an experimental allogeneic Natural Killer (NK) cell therapy engineered to express a Chimeric ILT Receptor (CIR™). The CIR construct is composed of the extracellular domain of Immunoglobulin-Like Transcript 2 (ILT2; also known as LILRB1 or CD85j) fused to the intracellular signaling domains of 4-1BB (TNFRSF9) and CD3ζ. This therapy specifically targets HLA-G, a non-classical MHC class I molecule that is frequently overexpressed in various cancers to mediate immune evasion. By utilizing the natural ILT2 receptor, the CIR-NK cells are designed to invert the inhibitory signal typically transmitted by HLA-G into an activating one, thereby triggering NK cell-mediated cytotoxicity against tumor cells. Developed by 1NKILT Therapeutics, this construct has been evaluated in preclinical models for the treatment of HLA-G-positive hematologic malignancies, including acute myeloid leukemia (AML) and multiple myeloma.
- Other names
- ILT2.4-1BB.CD3ζ CIR-NK cellsCIR-NK cellsILT2-CIR NK cellsILT-2-CIR NK cellsILT 2-CIR NK cells
02
Targets
HLA-G (Human leukocyte antigen G)
Beyond the preview
Go deeper on ILT2.4-1BB.CD3ζ CIR-NK cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ILT2.4-1BB.CD3ζ CIR-NK cells.